logo-loader
viewe-Therapeutics PLC

e-Therapeutics: Professor Malcolm Young becomes acting chairman

boardroom_350_54aa441a5f65e.jpg

e-Therapeutics (LON:ETX) said chief executive Professor Malcolm Young had become acting chairman of the group with effect from January 1.

It comes after Professor Oliver James's retirement from that role and as a non-executive director at the end of last year.

Brad Hoy, a non-executive director, will chair both the remuneration and audit committees in the interim, the firm told investors.

The biotech firm expects that an additional director will be appointed in due course.

Last month, e-Therapeutics said it had established the safe maximum dose for its potential cancer treatment and lead drug ETS2101.

This is a significant milestone in that it allows researchers to take the drug into the next stage of development.

Quick facts: e-Therapeutics PLC

Price: 11.875 GBX

AIM:ETX
Market: AIM
Market Cap: £49.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read